Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews · Infectious Diseases

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 20%Moderate 1 · 20%High 3 · 60%

Summary of findings: ACT vs CQ

Remaining parasitaemic at 24 hours · Adults and children with uncomplicated P. vivax malaria

Summary of findings: ACT leads to lower remaining parasitaemic at 24 hours compared with CQ (high certainty).

1 finding from 1 review

Artemisinin‐based combination therapy for treating uncomplicated Plasmodium vivax malaria 2013 · Cochrane Headline outcomes only
RR 0.42 [0.36, 0.5]
4 studies · 1652 participants
High

Summary of findings: ACT vs CQ

Remaining febrile after 24 hours · Adults and children with uncomplicated P. vivax malaria

Summary of findings: ACT probably leads to lower remaining febrile after 24 hours compared with CQ (moderate certainty).

1 finding from 1 review

Artemisinin‐based combination therapy for treating uncomplicated Plasmodium vivax malaria 2013 · Cochrane Headline outcomes only
RR 0.55 [0.43, 0.7]
2 studies · 990 participants
Moderate

Summary of findings: ACT vs CQ

Effective treatment of the blood stage parasite As assessed by: Recurrent parasitaemia before day 28 · Adults and children with uncomplicated P. vivax malaria

Summary of findings: ACT showed no clear difference in effective treatment of the blood stage parasite As assessed by:… compared with CQ (high certainty).

1 finding from 1 review

Artemisinin‐based combination therapy for treating uncomplicated Plasmodium vivax malaria 2013 · Cochrane Headline outcomes only
RR 0.58 [0.18, 1.9]
5 studies · 1622 participants
High

Summary of findings: ACT vs CQ

Post‐treatment prophylaxis As assessed by: Recurrent parasitaemia between day 28 and day 42/56/63 · Adults and children with uncomplicated P. vivax malaria

Summary of findings: ACT may leads to lower post‐treatment prophylaxis As assessed by: Recurrent parasitaemia… compared with CQ (low certainty).

1 finding from 1 review

Artemisinin‐based combination therapy for treating uncomplicated Plasmodium vivax malaria 2013 · Cochrane Headline outcomes only
RR 0.27 [0.08, 0.94]
1 study · 376 participants
Low

Summary of findings: ACT vs CQ

Serious adverse events · Adults and children with uncomplicated P. vivax malaria

Summary of findings: ACT showed no clear difference in serious adverse events compared with CQ (high certainty).

1 finding from 1 review

Artemisinin‐based combination therapy for treating uncomplicated Plasmodium vivax malaria 2013 · Cochrane Headline outcomes only
RR 1 [0.14, 7.04]
5 studies · 1775 participants
High